Arrowstreet Capital, Limited Partnership Nektar Therapeutics Transaction History

Arrowstreet Capital, Limited Partnership

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $2.18 Million - $4.21 Million	-150,500 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$15.87 - $23.12 $2.39 Million - $3.48 Million	150,500 New	150,500 $3.25 Million

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.